Pipeline
Our Pipeline
Avian Influenza Vaccine Vaccine (VXD1-AIV)
A next-gen recombinant-protein-based vaccine in preparation for high pandemic-risk HPAI (highly pathogenic avian influenza)
1. Platform overview
1) Pre-pandemic vaccine using self-assembling nanoparticle scaffolds
2) Nanoparticle antigen solubility expression using ChaperNova™
3) Microbe-based high-efficiency, low-cost production process
2. Antigen strategy
1) Design using the globally spreading H5 clade 2.3.4.4b
2) Target the HA globular domain derived from H5N1
3) Sequence integration based on the recently trending strain 2.3.4.4b clade
4) Integrated design with nanoparticle scaffold (ferritin)
5) Formation of a repeating antigen structure (24mer) through self-assembly
6) Stable production into a soluble form via the ChaperNova™ technology
Our Pipeline
Avian Influenza Vaccine(VXD1-AIV)
A next-gen recombinant-protein-based vaccine in preparation for high pandemic-risk HPAI (highly pathogenic avian influenza)
1. Platform overview
2. Antigen strategy
1) Design using the globally spreading H5 clade 2.3.4.4b
2) Target the HA globular domain derived from H5N1
3) Sequence integration based on the recently trending strain 2.3.4.4b clade
4) Integrated design with nanoparticle scaffold (ferritin)
5) Formation of a repeating antigen structure (24mer) through self-assembly
6) Stable production into a soluble form via the ChaperNova™ technology
Vaxdigm Co., Ltd.
CEO Sung Jae Kim
TEL 02-6205-2550
EMAIL hydrogold@vaxdigm.com
BUSINESS NUMBER 657-87-02464
ADDRESS 412ho, 201, Songpa-daero, Songpa-gu, Seoul, Republic of Korea
PRIVACY POLICYㅣTERMS AND CONDITIONS
COPYRIGHT © 2026 VAXDIGM. ALL RIGHTS RESERVED.
Vaxdigm Co., Ltd.
CEO Sung Jae Kim
EMAIL hydrogold@vaxdigm.com ㅣ TEL 02-6205-2550
BUSINESS NUMBER 657-87-02464 ㅣ ADDRESS 412ho, 201, Songpa-daero, Sonpa-gu, Seoul, Republic of Korea
PRIVACY POLICYㅣTERMS AND CONDITIONS
COPYRIGHT © 2026 VAXDIGM. ALL RIGHTS RESERVED.
